BioSpace News Archive

Seelos Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 15,700 restricted stock units to three newly-hired employees.

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 31,000 shares of Akebia’s common stock on November 30, 2023, as inducements material to such employee entering into employment with Akebia.

Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

GC Biopharma, a South Korean biopharmaceutical company, announced on November 30th that it has completed the construction mRNA production facility in its own vaccine production plant in Hwasun, Jeollanam-do, Korea, and will soon start the operation.

Opthea Limited announced an oral presentation featuring sozinibercept which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.

Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.

UCB, a global biopharmaceutical company, today unveiled its extensive program of 29 studies, including 4 late breakers, accepted for presentation at the AES Annual Meeting 2023, taking place from 1-5 December in Orlando, Florida.

Castle Biosciences, Inc. announced the publication of a study in the Journal of the Advanced Practitioner in Oncology that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.

Ovid Therapeutics Inc. today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.